Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Bristol Myers Squibb (BMS) has successfully defended itself against a high-profile antitrust lawsuit that accused the pharmaceutical giant of engaging in intellectual property (IP) fraud to delay generic competition f...
Share This Article
Ready-to-post copy includes the article link.
Bristol Myers Beats Pomalyst Antitrust Suit Alleging IP Fraud Bristol Myers Squibb (BMS) has successfully defended itself against a high-profile antitrust lawsuit that accused the pharmaceutical giant of engaging in intellectual property (IP) fraud to delay generic competition f... Read the full IIPLA article: https://iipla.org/news/bristol-myers-wins-pomalyst-ip-fraud-case